Jaroslav A Hubacek

Dr. Jaroslav A Hubacek

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
MSMartin Satny
Martin Satny
JHJaroslav A Hubacek
Jaroslav A Hubacek
MVMichal Vrablik
Michal Vrablik

Verified
Journal Article
Open access
PDF file
MVMichal Vrablik
Michal Vrablik
DDDana Dlouhá
Dana Dlouhá
VTVeronika Todorovová
Veronika Todorovová
JHJaroslav A Hubacek
Jaroslav A Hubacek
JHJaroslav A Hubacek
Jaroslav A Hubacek
Despite the rapid progress in diagnosis and treatment of cardiovascular disease (CVD), this disease remains a major cause of mortality and morbidity. Recent progress over the last two decades in the field of molecular genetics, especially with new tools such as genome-wide association studies, has helped to identify new genes and their variants, which can be used for calculations of risk, prediction of treatment efficacy, or detection of subjects prone to drug side effects. Although the use of genetic risk scores further improves CVD prediction, the significance is not unambiguous, and some subjects at risk remain undetected. Further research directions should focus on the “second level” of genetic information, namely, regulatory molecules (miRNAs) and epigenetic changes, predominantly DNA methylation and gene-environment interactions.

1 August 2010 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JHJaroslav A Hubacek
Jaroslav A Hubacek
VSVladimír Staněk
Vladimír Staněk
MGMarie Gebauerová
Marie Gebauerová
APAlexandra Pilipčincová
Alexandra Pilipčincová
DDDana Dlouhá
Dana Dlouhá
JPJan Piťha
Jan Piťha


1 January 2004
Verified
Journal Article
Closed access
JSJ Stefková
J Stefková
RPR Poledne
R Poledne
JHJaroslav A Hubacek
Jaroslav A Hubacek

14 February 2011 in Physiological Research
Verified
Journal Article
Closed access
JHJaroslav A Hubacek
Jaroslav A Hubacek
HPHynek Pikhart
Hynek Pikhart
APAnne Peasey
Anne Peasey
RKR. Kubínová
R. Kubínová
MBM. Bobák
M. Bobák
The FTO gene variants are the most important genetic determinants of body weight and obesity known so far, but the mechanism of their effect remains unclear. We have analyzed FTO rs17817449 variant (G>T in first intron) in 6024 adults aged 45-69 years to assess the potential mediating role of diet and physical activity. Diet was assessed by a 140-item food frequency questionnaire. Physical activity was measured by hours spent during a typical week by sport, walking and other activities outside of work requiring heavy and medium physical activity. Basal metabolic rate was calculated according Schofield formula. The FTO variant was significantly associated with body mass index (means in GG, GT and TT carriers were 28.7, 28.2 and 27.8 kg/m2, p<0.001) and basal metabolic rate (BMR) (means in GG, GT and TT were 1603, 1588 and 1576 kcal per day, respectively, p<0.008) but it was not associated with physical activity, total energy intake or with energy intakes from fat, carbohydrates, proteins or alcohol. Results were essentially similar in men and women and the adjustment for physical activity or dietary energy intake did not reduce the effect of the FTO polymorphism. Means of BMR per kg of body weight was lowest in GG carriers (20.09, 20.21 for GT and 20.30 for TT, p<0.006) and this effect was more pronounced in females. These results suggest that the effect of the FTO rs17817449 variant on BMI in Caucasian adults is not mediated by energy intake or physical activity, but some effect on BMR per kg of body weight is possible.